Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for vascular intrauterine growth restriction
IRCT20180819040830N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in intrauterine growth restriction (IUGR) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Neonatal birth weight. Started Dec 2019; status: completed.
02
Drugs
enoxaparin
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on IRCT20180819040830N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180819040830N4.